Navigation Links
Merck & Co., Inc. Response to Today's New York Medicaid Suit
Date:9/17/2007

WHITEHOUSE STATION, N.J., Sept. 17 /PRNewswire/ -- Merck & Co., Inc. today said that it has not yet received a complaint reportedly filed by New York State and New York City seeking Medicaid reimbursement costs. The Company intends to defend against the suit as it has defended against the Medicaid- related suits filed more than a year ago by a handful of other states.

Merck carefully studied VIOXX(R) before and after receiving U.S. Food and Drug Administration (FDA) approval, and consistently made the results of those studies available to the FDA and the medical and scientific communities. Merck acted responsibly from researching VIOXX prior to approval in clinical trials -- to monitoring the medicine while it was on the market -- to voluntarily withdrawing the medicine when it did. In fact, the Company acted within a week after one of its own studies suggested, for the first time, an increased relative risk with VIOXX compared to placebo which became apparent after about 18 months of continuous use.

The fact is that VIOXX worked for patients because it was effective at relieving pain with fewer gastrointestinal effects than other medicines in its class. Additionally, heart attacks and the injuries alleged in the suit were common before VIOXX was ever on the market and they remain common today. The medicine was labeled appropriately under the direction of the FDA according to the evolving science available at the time it was on the market.

Before today, Merck was facing six actions filed more than a year ago by the Attorneys General of the states of Alaska, Louisiana, Mississippi, Montana, Texas and Utah. All of the Attorney General suits seek to recover the Medicaid funds the states spent on the medicine. The Alaska, Louisiana, Mississippi, Montana and Utah cases are in the federal multi-district litigation (MDL) proceeding in New Orleans. The Texas proceeding is pending in Texas state court in Austin, Texas.

Status of Litigation

<
'/>"/>
SOURCE Merck & Co., Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. E Merck introduces Livogen Z with zinc sulphate
2. Merck to pay $ 253.5 million to Vioxx victim family
3. Merck and Takeda to collaborate in the sale of Cancer drug Matuzumab
4. Judgment In Favor Of Merck For Vioxx Drug
5. Merck, ICMR to conduct joint trials on cervical cancer vaccine
6. Merck in the Dock Due To Vioxx
7. Merck Says Januvia Effective In Type 2 Diabetes
8. Dr Reddys Launches Generic Version Of Mercks Proscar Tablets
9. Patency On Two Drugs From Merck & Pfizer’s To Expire Soo
10. Developing Nations to Get Gardasil at Lesser Rates from Merck Soon
11. Acid Test - Glaxos Cervarix, and Mercks Gardasil, Compete
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... September 16, 2014 Advanced Fertility Center ... named by Houstonia Magazine as one of the Top ... Houstonia Magazine - a metropolitan magazine serving the Houston ... and recognize them for their outstanding services. This accomplishment ... edition of Houstonia Magazine — a special publication listing ...
(Date:9/16/2014)... These new programs allow those who haven’t owned a ... $10,000 in a 0% interest free, 2nd down payment assistance ... federal programs, are listed on their private website. The $10,000 ... or move out of the property. The down payment assistance ... no monthly payments paid by the Borrower. The money is ...
(Date:9/16/2014)... Aspen Advisors, a U.S.-based healthcare IT ... for its high morale and collaborative culture ... Firms to Work For 2014.” Consulting magazine publishes ... 10,000 consultants participating across all major industries, representing more ... conducted, and firms were ranked in six categories - ...
(Date:9/16/2014)... 14, 2014 A new clinical trial ... and drug-eluting balloons (DEB) in treating in-stent ... EES provided superior late angiographic results and ... were reported today at the 26th annual ... by the Cardiovascular Research Foundation (CRF), TCT ...
(Date:9/16/2014)... Ensuring that corn absorbs the right balance of nitrogen, ... a Purdue and Kansas State University study finds. , ... from the U.S. and other regions showed that high ... plants took up key nutrients at specific ratios - ... nitrogen and potassium at a ratio of 1-to-1. These ...
Breaking Medicine News(10 mins):Health News:Dr. Michael Allon Receives Esteemed Recognition 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 3Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 2Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 3Health News:Results of RIBS IV trial reported at TCT 2014 2Health News:Boosting global corn yields depends on improving nutrient balance 2Health News:Boosting global corn yields depends on improving nutrient balance 3
... Optical technology is as accurate as colorectal tissue examination, ... Optical technology could help physicians detect small colorectal polyps ... , In the report, published online Nov. 10 in ... that the technique could replace histopathology, which requires more ...
... cancer has eliminated tumours in 50% of mice in a new ... the animals, the drug also stopped lung cancer tumours from growing ... Imperial College London, are now planning to take the drug into ... with an inoperable form of lung cancer. One in five ...
... 10 Reportlinker.com announces that a new ... catalogue. , Central Nervous System ... http://www.reportlinker.com/p0161866/Central-Nervous-System-Insomnia-or-Sleep-Disorders.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire , Life ... Sleep Disorders contains detailed information on the ...
... Hospital Dallas is the first hospital in Dallas and one ... Cycle III Chest Pain Center by the Society of Chest ... , "This honor means that Texas Health Presbyterian Dallas ranks ... collaborative treatment of heart attacks," said cardiologist Dr. John Harper, ...
... estimates 2,266 U.S. military veterans under the age of 65 died ... access to care. That figure is more than 14 times the ... 2008, and more than twice as many as have died (911 ... The researchers, who released their analysis today, pointedly say the health ...
... But researchers not exactly sure how pathogens raise risk of ... to several common pathogens may increase the risk of having ... Mitchell Elkind, an associate professor of neurology at Columbia University ... that the pathogens Chlamydia pneumoniae , Helicobacter pylori ...
Cached Medicine News:Health News:New Polyp Detection Method Could Be Cost-Saver 2Health News:Drug shrinks lung cancer tumors in mice 2Health News:Drug shrinks lung cancer tumors in mice 3Health News:Reportlinker Adds Central Nervous System Insomnia or Sleep Disorders 2Health News:Reportlinker Adds Central Nervous System Insomnia or Sleep Disorders 3Health News:Texas Health Dallas Receives Prestigious Chest Pain Accreditation 2Health News:Over 2,200 veterans died in 2008 due to lack of health insurance 2Health News:Common Infections May Contribute to Strokes 2Health News:Common Infections May Contribute to Strokes 3
(Date:9/16/2014)... 2014 /PRNewswire-iReach/ -- Dan York has been ... of the RTD ® Advanced Wound Care Dressing, ... sales presence in the U.S. Under York,s leadership, GWM ... field sales representatives in new sales territories that will ... add up to 20 sales representatives in major metropolitan ...
(Date:9/16/2014)... 2014 Adaptive Biotechnologies, a clinical stage diagnostics ... the adaptive immune system, is pleased to announce the ... Officer (CCO). The addition of Brain to the Company,s ... leading global healthcare companies, including Dean Schorno ... Genomic Health and Sean Nolan (CTO) from ...
(Date:9/16/2014)... , Sept. 16, 2014  Advanced Medical ... stage development company engaged primarily in the ... for diagnostic and therapeutic applications, today announced ... related to its brachytherapy products.  AMIC,s rights ... its license from Battelle, under which AMIC ...
Breaking Medicine Technology:GWM Products, LLC, announces U.S. market expansion. Dan York added as Director of Sales as part of nationwide growth initiative. 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 4
... IRVINE, Calif., June 12 Masimo (Nasdaq: ... Motion and Low-Perfusion pulse oximetry, announced today that three ... of Masimo PVI as a noninvasive and continuous measure ... week at the European Society of Anaesthesiology (ESA) Annual ...
... Safety and Biologic Activity Data Reviewed in End of Phase ... VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a ... treatment of cardiovascular and metabolic disease, announced today that an ... VIA-2291 (atreleuton), was recently held with the U.S. Food and ...
Cached Medicine Technology:New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 2New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 3New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 4New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 5New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 6VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 2VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 3VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 5
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Micro emulsifying needles, 18G....
Micro 2000, micro scissors micro 2000 supercut....
Yasargil clip applying forceps Mini. Stainless steel jaw....
Medicine Products: